Skip Navigation


Annals of Oncology Advance Access originally published online on May 26, 2005
Annals of Oncology 2005 16(8):1276-1282; doi:10.1093/annonc/mdi257
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/8/1276    most recent
mdi257v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brunello, A.
Right arrow Articles by Monfardini, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunello, A.
Right arrow Articles by Monfardini, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Adjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients{dagger}

A. Brunello1, U. Basso1,*, C. Pogliani1, A. Jirillo, C. Ghiotto1, H. Koussis1, F. Lumachi2, M. Iacobone2, L. Vamvakas3 and S. Monfardini1

1 Department of Medical Oncology, 2 Department of Endocrine Surgery, Azienda Ospedale–Università of Padova, Italy; 3 Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece

* Correspondence to: Dr U. Basso, Department of Medical Oncology-Direzione, Azienda Ospedale-Università, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy. Tel: +39-0498-215931; Fax: +39-0498-215932. Email: u.basso{at}tin.it

Background: Adjuvant chemotherapy in elderly women is currently perceived as one of the priorities in breast cancer (BC) research and, to date, we lack practical guidelines in this age group. Therefore we performed a retrospective analysis of the actual use of adjuvant chemotherapy according to each negative prognostic factor.

Patients and methods: Charts of all consecutive elderly patients aged 70 years or more with operable BC referred to our institution between 1999 and 2003 were reviewed for tumour stage and treatment, and compared with an equal cohort of younger randomly selected postmenopausal patients (control group).

Results: A total of 260 elderly patients (mean age 75.6 years, age range 70–97 years) with histological diagnosis of early BC were eligible. Conserving surgery was performed in 54.6% of patients, nodal dissection in 84.6% and sentinel node biopsy in 5.8%. Tumour size was pT2–pT3 in 45.4% of patients; grading was G3 in 27.3%, hormonal status was negative (HR–) in 16.9% and lymph nodes were involved (N+) in 36.1%. Of 188 patients presenting one or more risk factors (pT2–3, G3, N+, HR–), 48.4% were not proposed for adjuvant chemotherapy (compared with 7.2% in the control group), 39.8% of those with nodal involvement (compared with 4.3% of controls, P <0.0001) and 22.7% of those who were HR– (compared with 0.0% of controls, P=0.0002). Considering only patients receiving non-anthracycline-based chemotherapy, 20 elderly patients (25.9%) were unable to complete the planned number of cycles (compared with 4.7% of controls, P=0.0002). The 2-year disease-free survival was significantly decreased in N+ HR– patients compared with the remaining elderly patients (49.9% compared with 90.9%, P=0.0006).

Conclusions: Elderly BC patients receive much less adjuvant chemotherapy, according to each prognostic factor. N+ HR– disease probably represents the most reasonable indication. As the toxicity of the CMF regimen frequently caused interruption of treatment, alternative regimens should be assessed in this age class.

Key words: adjuvant chemotherapy, breast cancer, elderly


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
K. Hancke, M. D. Denkinger, J. Konig, C. Kurzeder, A. Wockel, D. Herr, M. Blettner, and R Kreienberg
Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study
Ann. Onc., October 13, 2009; (2009) mdp364v1.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Dellapasqua, M. Colleoni, M. Castiglione, and A. Goldhirsch
New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies
Oncologist, August 1, 2007; 12(8): 952 - 959.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G Mustacchi, M. Cazzaniga, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group
Breast cancer in elderly women: a different reality? Results from the NORA study
Ann. Onc., June 1, 2007; 18(6): 991 - 996.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Bouchardy, E. Rapiti, S. Blagojevic, A.-T. Vlastos, and G. Vlastos
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
J. Clin. Oncol., May 10, 2007; 25(14): 1858 - 1869.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.